drugset / Trial / NCT04507932
Characterizing Inflammatory Bowel Disease With 68Ga-FAPI PET/CT
NaSingle-groupOpen-labelDiagnostic
Summary
68Ga-FAPI has been developed as a tumor-targeting agent as fibroblast activation protein is overexpressed in cancer-associated fibroblasts and some inflammation,such as inflammatory bowel disease. And it might be more sensitive than FDG in detecting a certain type of inflammations according to our preliminary research. Thus this prospective study is going to investigate whether 68Ga-FAPI PET/CT may be superior for diagnosis, therapy response assessment and follow-up of inflammatory bowel disease than 18F-FDG PET/CT.
Timeline
- Start
- 2020-08-01
- Primary completion
- 2022-01-01
- Completion
- 2022-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | FAPI GA-68 | Diagnostic / imaging agent | — | Intravenous |